Innovent Biologics, Inc. (6IB.F)
| Previous Close | 4.6000 |
| Open | 4.9000 |
| Bid | 4.7000 x 0 |
| Ask | 5.1000 x 0 |
| Day's Range | 4.7000 - 4.9000 |
| 52 Week Range | 3.2400 - 5.6500 |
| Volume | |
| Avg. Volume | 8 |
| Market Cap | 7.999B |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings Date | Mar 20, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireHead-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical trial (DREAMS-2) of mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese subjects with type 2 diabetes (T2
PR NewswireInnovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343 as monotherapy for the treatment of claudin18.2-pos
PR NewswireInnovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announces the appointment of Dr. Samuel Zhang as its Global Chief Business Officer (CBO). In this role, Dr. Zhang will be responsible for Innovent's global strategy and business development, and his reporting line is Dr.
